PulseAI announced it has closed a seed funding round to expand deployment of its AI-enabled electrocardiogram (ECG) diagnostics platform and progress toward U.S. FDA 510(k) clearance, positioning the company to commercialize clinical decision-support tools for both primary care and acute care environments.
The round was led by Innovation Ulster Limited, with participation from The Mortara Group and The Francis Crick Institute. Financial terms were not disclosed.
PulseAI is targeting a longstanding bottleneck in cardiovascular care: while more than 300 million ECGs are performed globally each year, interpretation quality and speed can vary widely due to reliance on specialist training and manual review. The company said its AI-ECG platform is designed to deliver high-performance decision support that can reduce diagnostic variability, shorten time to insight, and improve the odds of earlier intervention.
As part of the financing, Dr. Justin Mortara—an ECG technology veteran and former CEO of Mortara Instruments—will join PulseAI as chair of the board. PulseAI said the appointment is intended to strengthen the company’s alignment with cardiac monitoring and diagnostics leaders as it moves through regulatory milestones and pursues broader integration into clinical workflows.
The company said its models are trained on large-scale ECG datasets and have been validated through collaborations with institutions across Europe and the United States. With the new capital, PulseAI plans to advance regulatory work, including preparation for an FDA 510(k) submission, expand clinical validation across diverse populations and care settings, further productize the platform for enterprise and OEM use cases, and broaden partnerships with device manufacturers and hospital networks. The company also sees an opportunity to extend AI-assisted ECG interpretation beyond traditional devices, including across a growing set of consumer wearables.
KEY QUOTES:
“This investment marks a pivotal moment for PulseAI as we move into full clinical and regulatory execution. Our goal is to deliver advanced ECG technology that can expedite and improve the accuracy of cardiac diagnostics, reducing variability and expanding access to high-quality diagnostics in all areas of healthcare.”
Dr. Alan Kennedy, Founder and CEO, PulseAI
“PulseAI sits at the intersection of clinical rigour, scalable technology, and real market need. The company is building a platform with the potential to elevate ECG interpretation across the entire care continuum, pairing its AI with traditional medical devices as well as a growing array of consumer wearables. I’m excited to support the team as they move through regulatory milestones to broader industry adoption”
Justin Mortara, Incoming Chair of the Board, PulseAI
